Shuttle Pharmaceuticals Holdings EBIT

Shuttle Pharmaceuticals Holdings posts a EBIT of $-11M as of March 2026. That compares with $-8.9M in the prior-year period — down 23.6% year over year. That is above the sector sector average of $-63M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Shuttle Pharmaceuticals Holdings's EBIT was $-8.9M. The latest reading is $-11M — a 23.6% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a EBIT near $-63M is typical. Shuttle Pharmaceuticals Holdings's $-11M is higher that level. That is roughly 82.4% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Shuttle Pharmaceuticals Holdings's financial statement story. At $-11M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SHPH's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $-63M), and (3) consistency with growth and profitability. This page covers the first two; Shuttle Pharmaceuticals Holdings's other metric pages and overview cover the third.